Medroxyprogesterone acetate (MPA) can increase the expression of CD44 and the activity of ALDH1A1 in BCSCs, enhance the tumorigenesis of CSCs and block cholesterol synthesis, which can reduce the formation of tumor spheres in BCSCs [81]. Here, ALDH1A1 is linked to neoplasm.